发布求助
文献互助 智能选刊 最新文献

Medical Letter on Drugs and Therapeutics最新文献

筛选
英文 中文
Vonoprazan (Voquezna) for erosive esophagitis. 治疗侵蚀性食管炎的 Vonoprazan（Voquezna）。
IF 1.9 4区 医学
Medical Letter on Drugs and Therapeutics Pub Date : 2023-12-25 DOI: 10.58347/tml.2023.1692b
{"title":"Vonoprazan (Voquezna) for erosive esophagitis.","authors":"","doi":"10.58347/tml.2023.1692b","DOIUrl":"10.58347/tml.2023.1692b","url":null,"abstract":"","PeriodicalId":54742,"journal":{"name":"Medical Letter on Drugs and Therapeutics","volume":"65 1692","pages":"203-205"},"PeriodicalIF":1.9,"publicationDate":"2023-12-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138833049","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Tirzepatide (Zepbound) for chronic weight management. 用于慢性体重控制的 Tirzepatide（Zepbound）。
IF 1.9 4区 医学
Medical Letter on Drugs and Therapeutics Pub Date : 2023-12-25 DOI: 10.58347/tml.2023.1692c
{"title":"Tirzepatide (Zepbound) for chronic weight management.","authors":"","doi":"10.58347/tml.2023.1692c","DOIUrl":"10.58347/tml.2023.1692c","url":null,"abstract":"","PeriodicalId":54742,"journal":{"name":"Medical Letter on Drugs and Therapeutics","volume":"65 1692","pages":"205-207"},"PeriodicalIF":1.9,"publicationDate":"2023-12-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138833048","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Drugs for depressionr. 治疗抑郁症的药物r.
IF 1.9 4区 医学
Medical Letter on Drugs and Therapeutics Pub Date : 2023-12-11 DOI: 10.58347/tml.2023.1691a
{"title":"Drugs for depressionr.","authors":"","doi":"10.58347/tml.2023.1691a","DOIUrl":"10.58347/tml.2023.1691a","url":null,"abstract":"","PeriodicalId":54742,"journal":{"name":"Medical Letter on Drugs and Therapeutics","volume":"65 1691","pages":"193-200"},"PeriodicalIF":1.9,"publicationDate":"2023-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138833046","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Shockwave therapy for erectile dysfunction. 冲击波治疗勃起功能障碍。
IF 1.9 4区 医学
Medical Letter on Drugs and Therapeutics Pub Date : 2023-11-27 DOI: 10.58347/tml.2023.1690d
{"title":"Shockwave therapy for erectile dysfunction.","authors":"","doi":"10.58347/tml.2023.1690d","DOIUrl":"10.58347/tml.2023.1690d","url":null,"abstract":"Low-intensity extracorporeal shockwave therapy similar to that used to fragment kidney stones or gallstones is a new option for treatment of erectile dysfunction that is now being advertised extensively in the US. It has not been approved by the FDA for treatment of erectile dysfunction.","PeriodicalId":54742,"journal":{"name":"Medical Letter on Drugs and Therapeutics","volume":"65 1690","pages":"190-191"},"PeriodicalIF":1.9,"publicationDate":"2023-11-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138178013","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparison chart: Antiviral drugs for influenza for 2023-2024. 对比图：2023-2024年流感抗病毒药物。
IF 1.9 4区 医学
Medical Letter on Drugs and Therapeutics Pub Date : 2023-11-13 DOI: 10.58347/tml.2023.1689e
{"title":"Comparison chart: Antiviral drugs for influenza for 2023-2024.","authors":"","doi":"10.58347/tml.2023.1689e","DOIUrl":"10.58347/tml.2023.1689e","url":null,"abstract":"Comparison chart of antiviral drugs for influenza for 2023-2024.","PeriodicalId":54742,"journal":{"name":"Medical Letter on Drugs and Therapeutics","volume":"65 1689","pages":"e1-e6"},"PeriodicalIF":1.9,"publicationDate":"2023-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71489084","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
COVID-19 update: New Novavax vaccine formulation for 2023-2024. 新冠肺炎更新：2023-2024年新的诺瓦瓦克斯疫苗配方。
IF 1.9 4区 医学
Medical Letter on Drugs and Therapeutics Pub Date : 2023-11-13 DOI: 10.58347/tml.2023.1689b
{"title":"COVID-19 update: New Novavax vaccine formulation for 2023-2024.","authors":"","doi":"10.58347/tml.2023.1689b","DOIUrl":"10.58347/tml.2023.1689b","url":null,"abstract":"A new 2023-2024 formulation of the adjuvanted protein subunit COVID-19 vaccine manufactured by Novavax that was developed to more closely target currently circulating SARS-CoV-2 variants has been made available in the US under an FDA Emergency Use Authorization (EUA) for use in persons ≥12 years old. The original formulation of the Novavax vaccine is no longer authorized for use in the US. In September, updated formulations of the mRNA COVID-19 vaccines manufactured by Pfizer/BioNTech (Comirnaty) and Moderna (Spikevax) were licensed by the FDA for use in persons ≥12 years old and made available under EUAs for use in persons 6 months to 11 years old.","PeriodicalId":54742,"journal":{"name":"Medical Letter on Drugs and Therapeutics","volume":"65 1689","pages":"182-183"},"PeriodicalIF":1.9,"publicationDate":"2023-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71489085","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correction. 修正。
IF 1.9 4区 医学
Medical Letter on Drugs and Therapeutics Pub Date : 2023-11-13 DOI: 10.58347/tml.2023.1689d
{"title":"Correction.","authors":"","doi":"10.58347/tml.2023.1689d","DOIUrl":"10.58347/tml.2023.1689d","url":null,"abstract":"In our article in issue 1687 on the updated 2023-2024 COVID-19 vaccines from Pfizer and Moderna (Med Lett Drugs Ther 2023; 65:161), the doses and formulations of the Pfizer vaccine were incorrect. A revised table has been posted in the online version of the article.","PeriodicalId":54742,"journal":{"name":"Medical Letter on Drugs and Therapeutics","volume":"65 1689","pages":"184"},"PeriodicalIF":1.9,"publicationDate":"2023-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138178008","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Antiviral drugs for influenza for 2023-2024. 2023-2024年流感抗病毒药物。
IF 1.9 4区 医学
Medical Letter on Drugs and Therapeutics Pub Date : 2023-11-13 DOI: 10.58347/tml.2023.1689a
{"title":"Antiviral drugs for influenza for 2023-2024.","authors":"","doi":"10.58347/tml.2023.1689a","DOIUrl":"10.58347/tml.2023.1689a","url":null,"abstract":"Influenza is generally a self-limited illness, but pneumonia, respiratory failure, and death can occur, especially in patients at increased risk for influenza complications (see Table 1). Antiviral drugs recommended for treatment and chemoprophylaxis of influenza for the 2023-2024 season are listed in Table 2. Updated information on influenza activity and antiviral resistance is available from the CDC at www.cdc.gov/flu.","PeriodicalId":54742,"journal":{"name":"Medical Letter on Drugs and Therapeutics","volume":"65 1689","pages":"177-182"},"PeriodicalIF":1.9,"publicationDate":"2023-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71489083","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
In brief: Empagliflozin (Jardiance) for chronic kidney disease. 简言之：恩帕列嗪（Jardiance）治疗慢性肾脏疾病。
IF 1.9 4区 医学
Medical Letter on Drugs and Therapeutics Pub Date : 2023-11-13 DOI: 10.58347/tml.2023.1689c
{"title":"In brief: Empagliflozin (Jardiance) for chronic kidney disease.","authors":"","doi":"10.58347/tml.2023.1689c","DOIUrl":"10.58347/tml.2023.1689c","url":null,"abstract":"The sodium-glucose cotransporter 2 (SGLT2) inhibitor empagliflozin (Jardiance – Boehringer Ingelheim/Lilly) is now FDA-approved to reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, and hospitalization in adults with chronic kidney disease (CKD) at risk of progression. It is also approved to improve glycemic control in patients ≥10 years old with type 2 diabetes, to reduce the risk of cardiovascular death and hospitalization for heart failure (HF) in adults with HF, and to reduce the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease.","PeriodicalId":54742,"journal":{"name":"Medical Letter on Drugs and Therapeutics","volume":"65 1689","pages":"183-184"},"PeriodicalIF":1.9,"publicationDate":"2023-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71489086","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Drugs for gout. 治疗痛风的药物。
IF 1.9 4区 医学
Medical Letter on Drugs and Therapeutics Pub Date : 2023-10-30 DOI: 10.58347/tml.2023.1688a
{"title":"Drugs for gout.","authors":"","doi":"10.58347/tml.2023.1688a","DOIUrl":"10.58347/tml.2023.1688a","url":null,"abstract":"Drugs for gout are used to reduce the pain and inflammation of acute flares, decrease the frequency of exacerbations, and lower serum urate levels to prevent recurrent flares, development of tophi, and joint damage.","PeriodicalId":54742,"journal":{"name":"Medical Letter on Drugs and Therapeutics","volume":"65 1688","pages":"169-175"},"PeriodicalIF":1.9,"publicationDate":"2023-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49694087","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信